A randomized, double-blind clinical trial from Chile shows that full-spectrum Cannabis sativa extract, combined with standard painkillers, slashed pain scores by nearly 40% in dogs with chronic osteoarthritis — with no adverse effects observed.
Every dog owner who has watched their senior pet struggle to climb stairs, hesitate before jumping onto the couch, or whimper at a simple stretch knows what chronic pain looks like. Chronic osteoarthritis — the slow, joint-grinding disease that strikes millions of aging dogs worldwide — is one of the most undertreated conditions in veterinary medicine. Standard anti-inflammatory drugs often lose their edge over time, carry organ-damaging side effects, and leave many animals without satisfactory relief. Now, a landmark peer-reviewed study published this month in the journal Animals (MDPI) suggests that a carefully dosed, full-spectrum Cannabis sativa oil extract may change that equation — dramatically, and safely.
The research team, led by veterinary scientists at Universidad Mayor in Santiago, Chile, ran a six-week randomized, double-blind, placebo-controlled trial — the gold standard of clinical research — in 27 dogs diagnosed with chronic osteoarthritis. By the end of the study, dogs receiving cannabis oil alongside conventional medication showed nearly a 40% reduction in pain scores, while more than half improved their disease stage on a validated clinical scale. No dog experienced any adverse effects.
Key Takeaways
- Dogs treated with full-spectrum cannabis oil plus conventional drugs saw a 39.6% drop in pain scores by day 28 — versus just 24.7% in the placebo group and a 1.6% increase in the control group.
- Over 55% of dogs in the cannabis group improved one full clinical stage on the Canine Osteoarthritis Staging Tool (COAST), moving from severe (stage 4) to moderate (stage 3). No improvement was seen in the other groups.
- Zero adverse effects were reported across the entire six-week trial, including in geriatric dogs and those on multiple medications.
- The extract used was a full-spectrum RSO preparation containing not just CBD, but also CBDA, THC, and THCA — compounds researchers believe work better together than alone.
- This is reportedly the first cannabis pain study of its kind conducted in Chile, and the first to specifically highlight the clinical role of acidic cannabinoids (CBDA, THCA) in a veterinary setting.
The Hidden Epidemic in Your Dog’s Joints
Chronic osteoarthritis is not just a problem for aging humans. It is estimated to affect up to 20% of dogs over one year of age and a staggering 80% of dogs over eight. It is a progressive, degenerative disease in which joint cartilage breaks down over time, causing inflammation, bone-on-bone friction, and chronic pain. Breeds prone to hip dysplasia — German Shepherds, Labrador Retrievers, Golden Retrievers — are especially vulnerable, but any dog can develop it.
The standard toolkit of veterinary medicine includes non-steroidal anti-inflammatory drugs (NSAIDs) like carprofen and meloxicam, and nerve-pain medications like pregabalin. These treatments can help, but they are far from perfect. Long-term NSAID use is associated with kidney and liver stress. Some dogs develop drug tolerance. Others simply don’t respond adequately. And for many pet owners, watching their companion suffer while the medication options are running out is heartbreaking.
This is the gap that the Chilean research team — and the growing body of cannabis veterinary science worldwide — is trying to fill.
What Exactly Was Tested — And How
The study enrolled 27 dogs, all over seven years of age, all clinically confirmed to have chronic osteoarthritis at Stage 4 — the most severe level on the COAST scale. All had previously been treated with NSAIDs but had failed to achieve satisfactory pain control. Before the trial began, every dog underwent a one-week drug washout period, full blood work, and X-rays of their affected joints.
The dogs were randomly assigned to three groups of nine. The first group received a full-spectrum Cannabis sativa oil extract alongside their conventional NSAID and pregabalin treatment. The second group received a placebo oil (odorless extra virgin olive oil) alongside the same conventional treatment. The third group received only conventional treatment, with no oil at all. Crucially, neither owners nor attending veterinarians knew which dogs were receiving the real cannabis extract — satisfying the requirements of a true double-blind design.
The cannabis extract itself was a Rick Simpson Oil (RSO)-method preparation standardized in olive oil, containing four key cannabinoids: CBD (Cannabidiol), CBDA (Cannabidiolic acid), THC (Delta-9-Tetrahydrocannabinol), and THCA (Tetrahydrocannabinolic acid). Lab analysis confirmed the total cannabinoid concentration at 46.4 mg/mL, with CBDA and CBD as the dominant compounds (background on what CBD is and how it works is in our guide).
Dosing started gently — around 0.1 mg/kg — and escalated every 72 hours by a single drop over the course of four weeks, until a maximum tolerated dose of 2 mg/kg was reached. That final dose was then maintained for the remaining two weeks of the study. Pain was tracked weekly using two validated instruments: the Canine Brief Pain Inventory (CBPI), a 10-item questionnaire completed by owners, and the COAST staging scale, assessed by veterinarians.
The Results: A Story Told in Numbers
By day 28 — the point at which the maximum tolerated dose had been in place for two weeks — the differences between the groups were striking.
The cannabis group’s average pain score fell from 47 at baseline to 31, a reduction of approximately 39.6%. The placebo group dropped from 59 to 45, a reduction of 24.7% — a meaningful result that the researchers attribute in part to the anti-inflammatory properties of olive oil itself. The control group, meanwhile, saw its average pain score edge upward from 48 to 48.5, a 1.6% increase, suggesting that conventional drugs alone were essentially losing the battle against the disease’s progression.
Statistical analysis confirmed that the difference between the cannabis group and the control group was significant (p = 0.019). On the COAST scale, 55.5% of dogs in the cannabis group moved from stage 4 to stage 3. Not one dog in the placebo or control groups showed any stage improvement.
Perhaps the most reassuring finding of all: across the entire six-week trial, not a single dog in the cannabis group experienced a reported adverse effect — no sedation, no gastrointestinal upset, no signs of THC toxicity. This held true even for the smallest dogs in the group, weighing as little as 9 kg.
Why Full-Spectrum May Be the Key Ingredient
Much of the existing veterinary research on cannabis and pain has focused exclusively on CBD oil. This new study adds a critical dimension: the full-spectrum approach, meaning the extract preserves a wide range of plant compounds working together.
The so-called “entourage effect” is the hypothesis — increasingly supported by evidence — that cannabinoids, terpenes, and flavonoids work synergistically, each amplifying and modulating the others’ effects. The acidic forms of cannabinoids, CBDA and THCA, are particularly important here. Unlike CBD and THC, their heat-processed counterparts, the acidic precursors are found in the raw plant and have distinct pharmacological profiles. CBDA, for instance, has been shown to act as a selective COX-2 inhibitor — the same enzyme pathway targeted by many common anti-inflammatory drugs.
Research has also shown that CBDA and THCA may be absorbed more efficiently than their neutral forms in dogs, and that CBDA can actually boost the absorption and retention of CBD in the bloodstream. This pharmacokinetic advantage may help explain why the full-spectrum formula outperformed not just the control group, but also the placebo group receiving the same conventional medications.
The terpenes in the extract — compounds like beta-myrcene, alpha-pinene, and beta-caryophyllene — are also thought to contribute analgesic and anti-inflammatory effects of their own, a point the study authors support with citations from the broader terpene science literature.
What This Means for Pet Owners — and the Bigger Picture
For anyone who has a dog with arthritis, the study’s conclusion is significant: full-spectrum cannabis oil, administered carefully at appropriate doses alongside conventional treatment, may offer a meaningful improvement in quality of life — both in terms of pain reduction and functional mobility — and the evidence from this trial suggests it does so safely.
That said, the researchers are candid about limitations. The sample size of 27 dogs is small. The dogs received different combinations of conventional drugs, which introduces some variability. The study lasted only six weeks, leaving open questions about long-term effects. And while the statistical difference between the cannabis and control groups was clear, the difference between the cannabis and placebo groups did not reach formal statistical significance — a gap that future, larger studies will need to address.
The authors explicitly call for larger, longer, and more standardized trials. But they also raise a point that extends well beyond joint pain: if cannabinoid-based therapy can safely and effectively complement conventional treatment in veterinary patients, it opens the door to similar research across a range of conditions. Behavioral science is already moving in that direction — recent findings suggest CBD may reduce aggression in dogs, pointing to a broader role for cannabinoids in canine wellness that goes far beyond the musculoskeletal system. And if full-spectrum cannabis therapy proves effective and safe across multiple conditions in animals, it will inevitably reinvigorate the conversation about its use in humans with chronic inflammatory diseases like rheumatoid arthritis.
For now, if you’re a pet owner considering cannabis products for a dog with arthritis, the emerging science suggests real promise — but also underscores the importance of working with a veterinarian who understands cannabinoid dosing, product quality, and monitoring. Not all CBD or cannabis products are created equal, and the standardized, lab-verified extract used in this study is a far cry from generic pet CBD treats on the market.
FAQ
Many veterinarians in countries where cannabis-derived products are legal are already discussing this option with clients. However, it is critical to use only products that have been third-party lab tested for cannabinoid content, are formulated specifically for animals, and are used under veterinary supervision. Dogs metabolize THC very differently from humans and can experience toxicity at doses far lower than those affecting people. Never use human recreational cannabis products on your pet.
This is one of the most common concerns — and it’s legitimate. Dogs are known to be more sensitive to THC than humans. The key in this study was a very slow, careful dose escalation protocol, starting at just 0.1 mg/kg and building over four weeks with ongoing veterinary monitoring. This approach resulted in zero adverse effects across all nine dogs in the cannabis group, including the smallest animals. Precise, individualized dosing under professional supervision is essential.
A standard CBD-only oil contains primarily one cannabinoid. A full-spectrum extract retains the complete natural chemical profile of the cannabis plant — multiple cannabinoids (CBD, CBDA, THC, THCA), terpenes, and flavonoids. These compounds are thought to enhance each other’s therapeutic effects through the entourage effect. This study used a full-spectrum product and produced markedly better results than studies using CBD alone have typically reported.
The study authors explicitly raise this possibility. The endocannabinoid system — the biological network of receptors that cannabinoids interact with — exists in both humans and dogs. The same CB1, CB2, and TRPV1 receptors involved in canine pain modulation are also present in human joints. While veterinary research cannot be directly extrapolated to humans, it adds to a growing body of evidence supporting multi-cannabinoid therapies for chronic inflammatory pain — a finding with obvious implications for millions of people worldwide.
Disclaimer
This article is for informational and educational purposes only and does not constitute veterinary or medical advice. The content is based on a peer-reviewed academic study and is intended to communicate its findings to a general audience. Cannabis-derived products for animals are subject to varying legal restrictions depending on jurisdiction. Always consult a licensed veterinarian before starting, changing, or stopping any treatment for your pet. The Cannex and its editorial team do not endorse any specific product, brand, or treatment protocol. Individual results may vary.
